ZA972843B - Cyclic adhesion inhibitors. - Google Patents

Cyclic adhesion inhibitors.

Info

Publication number
ZA972843B
ZA972843B ZA9702843A ZA972843A ZA972843B ZA 972843 B ZA972843 B ZA 972843B ZA 9702843 A ZA9702843 A ZA 9702843A ZA 972843 A ZA972843 A ZA 972843A ZA 972843 B ZA972843 B ZA 972843B
Authority
ZA
South Africa
Prior art keywords
adhesion inhibitors
cyclic adhesion
cyclic
inhibitors
adhesion
Prior art date
Application number
ZA9702843A
Other languages
English (en)
Inventor
Alfred Jonczyk
Simon L Goodman
Beate Diefenbach
Horst Kessler
Marcus Koppitz
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA972843B publication Critical patent/ZA972843B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA9702843A 1996-04-06 1997-04-03 Cyclic adhesion inhibitors. ZA972843B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19613933A DE19613933A1 (de) 1996-04-06 1996-04-06 Cyclische Adhäsionsinhibitoren

Publications (1)

Publication Number Publication Date
ZA972843B true ZA972843B (en) 1998-02-19

Family

ID=7790744

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9702843A ZA972843B (en) 1996-04-06 1997-04-03 Cyclic adhesion inhibitors.

Country Status (24)

Country Link
US (1) US6127335A (sk)
EP (1) EP0904285B1 (sk)
JP (1) JP4115530B2 (sk)
KR (1) KR100438378B1 (sk)
CN (1) CN1119351C (sk)
AR (1) AR006523A1 (sk)
AT (1) ATE224402T1 (sk)
AU (1) AU717496B2 (sk)
BR (1) BR9708530A (sk)
CA (1) CA2250861C (sk)
CZ (1) CZ291510B6 (sk)
DE (2) DE19613933A1 (sk)
DK (1) DK0904285T3 (sk)
ES (1) ES2183159T3 (sk)
HU (1) HUP9903631A3 (sk)
NO (1) NO984667L (sk)
PL (1) PL187924B1 (sk)
PT (1) PT904285E (sk)
RU (1) RU2184121C2 (sk)
SK (1) SK283718B6 (sk)
TW (1) TW570929B (sk)
UA (1) UA61071C2 (sk)
WO (1) WO1997038009A1 (sk)
ZA (1) ZA972843B (sk)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038718A2 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Use of matrix metalloproteinase inhibitor together with an antineoplastic agents, optionally also together with radiation, in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
UA71608C2 (en) 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
SK5902003A3 (en) 2000-11-01 2003-08-05 Merck Patent Gmbh Methods and compositions for the treatment of diseases of the eye
US20040029788A1 (en) * 2000-11-01 2004-02-12 Hans-Markus Bender Methods and compositions for the treatment of diseases of the eye
JP4499327B2 (ja) * 2001-12-06 2010-07-07 松崎 浩巳 拡径器具および手術器具セット
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
CA2478239A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
EP1483251B1 (en) 2002-03-12 2009-12-23 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
ITRM20020402A1 (it) * 2002-07-29 2004-01-29 Sigma Tau Ind Farmaceuti Derivati fluoro-alchil-ciclopeptidi ad attivita' anti-integrine.
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
AR041010A1 (es) * 2002-08-16 2005-04-27 Janssen Pharmaceutica Nv Compuestos de acido piperidinoil carboxilico utiles como antagonistas selectivos del receptor de integrina
WO2004066956A2 (en) * 2003-01-30 2004-08-12 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
CN101990425B (zh) * 2008-04-08 2016-01-20 默克专利股份有限公司 包含环肽的组合物和使用方法
US10745444B2 (en) 2017-04-17 2020-08-18 National Tsing Hua University Cyclopeptide, pharmaceutical or cosmetic composition comprising the same and method for preparing the same
EP3392262B1 (en) * 2017-04-17 2021-08-18 National Tsing Hua University Cyclopeptide, pharmaceutical or cosmetic composition comprising the same and method for preparing the same
US10494403B2 (en) 2018-03-06 2019-12-03 Ciphore Biomed Technology Limited Company Cyclopeptide, pharmaceutical or cosmetic composition comprising the same and method for preparing the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1077279A (zh) * 1992-04-09 1993-10-13 北京矿冶研究总院 雷管桥丝发火电阻安全检测仪
UA43823C2 (uk) * 1992-07-06 2002-01-15 Мерк Патент Геселлшафт Міт Бесшренктер Хафтунг ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ІНТЕГРИН <font face="Symbol">a</font><sub>V</sub><font face="Symbol">b</font><sub>3</sub>-ОПОСЕРЕДКОВАНОЇ КЛІТИННОЇ АДГЕЗІЇ КЛІТИН ССАВЦІВ, СПОСІБ ЛІКУВАННЯ ТА ПРОФІЛАКТИКИ ЗАХВОРЮВАННЯ, АСОЦІЙОВАНОГО З ПОРУШЕННЯМ АДГЕЗІЇ КЛІТИН, СПОСІБ БЛОКУВАННЯ ЗВ'ЯЗУВАННЯ ФІБРИНОГЕНОМ ІНТЕГРИНУ, КОМПОЗИЦІЯ ДЛЯ ЗАГОЄННЯ РАН
DE4310643A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren

Also Published As

Publication number Publication date
CA2250861A1 (en) 1997-10-16
AU2568897A (en) 1997-10-29
DK0904285T3 (da) 2003-01-27
EP0904285A1 (de) 1999-03-31
PT904285E (pt) 2003-02-28
CA2250861C (en) 2008-07-15
NO984667D0 (no) 1998-10-06
UA61071C2 (en) 2003-11-17
ATE224402T1 (de) 2002-10-15
PL187924B1 (pl) 2004-11-30
PL329154A1 (en) 1999-03-15
US6127335A (en) 2000-10-03
BR9708530A (pt) 1999-08-03
CZ291510B6 (cs) 2003-03-12
RU2184121C2 (ru) 2002-06-27
AU717496B2 (en) 2000-03-30
DE19613933A1 (de) 1997-10-09
KR20000005210A (ko) 2000-01-25
TW570929B (en) 2004-01-11
HUP9903631A3 (en) 2000-04-28
KR100438378B1 (ko) 2004-08-25
WO1997038009A1 (de) 1997-10-16
AR006523A1 (es) 1999-09-08
EP0904285B1 (de) 2002-09-18
CZ320398A3 (cs) 1999-01-13
JP2000510102A (ja) 2000-08-08
NO984667L (no) 1998-10-06
CN1218478A (zh) 1999-06-02
JP4115530B2 (ja) 2008-07-09
SK136498A3 (en) 1999-05-07
HUP9903631A2 (hu) 2000-03-28
SK283718B6 (sk) 2003-12-02
ES2183159T3 (es) 2003-03-16
CN1119351C (zh) 2003-08-27
DE59708269D1 (de) 2002-10-24

Similar Documents

Publication Publication Date Title
PL316071A1 (en) Cyclic adhesion inhibitors
ZA977969B (en) Reflux inhibitors.
ZA977086B (en) NAALADase inhibitors.
PL331338A1 (en) Thiosulphonamidic metaloprotease inhibitors
ZA9710429B (en) Broad-spectrumδ-endotoxins.
AU4073997A (en) 1,4-heterocyclic metallprotease inhibitors
ZA979199B (en) Aminothiophenecarboxamides.
ZA976168B (en) 3-Ureido-pyridofurans and -pyridothiophenes.
ZA972843B (en) Cyclic adhesion inhibitors.
ZA977206B (en) Arylalkanoylpyridazines.
ZA978304B (en) 3-alkyl-3-phenyl-piperidines.
PL331803A1 (en) Bidonoric metaloprotease inhibitors
ZA97572B (en) 1-pyrazol-3-ylethyl-4-indol-3-ylpiperidines.
ZA9710860B (en) Adhesives.
ZA974779B (en) Thrombin inhibitors.
ZA977209B (en) Thrombin inhibitors.
ZA974052B (en) New benzothiazolinones.
ZA976022B (en) Cycloalkano-pyridines.
ZA971466B (en) Endothelin-receptor-antagonists.
ZA974056B (en) New thiazolopyridines.
SI0904285T1 (en) Cyclic adhesion inhibitors
ZA971474B (en) Endothelin-receptor-antagonists.
ZA934819B (en) Cyclic adhesion inhibitors.
ZA975469B (en) X14-mannitol.
ZA977142B (en) Belt-lock.